On or around 01/22/2020 (Notice of voluntarily dismissal)
Filing Date: October 23, 2019
According to the Complaint, Fibrocell Science, Inc. is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue.
This action stems from a proposed transaction announced on September 12, 2019, pursuant to which Fibrocell will be acquired by Castle Creek Pharmaceutical Holdings, Inc.
On September 12, 2019, Fibrocell’s Board of Directors caused the Company to enter into an agreement and plan of merger with Castle Creek. Pursuant to the terms of the Merger Agreement, Fibrocell’s stockholders will receive $3.00 in cash for each share of Fibrocell common stock they own.
On October 11, 2019, Defendants filed a proxy statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading.
This case was voluntarily dismissed on January 22, 2020.
Company & Securities Information
Defendant: Fibrocell Science, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: FCSC
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Adam Franchi, et al. v. Fibrocell Science, Inc., et al.
COURT: D. Delaware
DOCKET #: 19-CV-02001
JUDGE: Hon. Colm F. Connolly
DATE FILED: 10/23/2019
CLASS PERIOD START: 09/12/2019
CLASS PERIOD END: 10/23/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available